



(11) **EP 2 753 642 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07K 14/605^(2006.01) A61K 38/26^(2006.01)

(48) Corrigendum issued on:
13.12.2017 Bulletin 2017/50

(86) International application number:
PCT/EP2012/067364

(45) Date of publication and mention
of the grant of the patent:
01.03.2017 Bulletin 2017/09

(87) International publication number:
WO 2013/037690 (21.03.2013 Gazette 2013/12)

(21) Application number: **12805429.3**

(22) Date of filing: **06.09.2012**

(54) **GLP-1 DERIVATIVES**

GLP-1-DERIVATE

DÉRIVÉS DE GLP-1

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(74) Representative: **Pedersen, Karen Oestergaard et
al**
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd (DK)

(30) Priority: **06.09.2011 EP 11180265**
08.09.2011 US 201161532323 P

(56) References cited:
WO-A1-94/13313 WO-A2-2011/080102
US-A- 5 525 491 US-A- 5 663 907

(43) Date of publication of application:
16.07.2014 Bulletin 2014/29

(73) Proprietor: **Novo Nordisk A/S**
2880 Bagsværd (DK)

- **KNUDSEN LOTTE B ET AL: "Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 43, no. 9, 4 May 2000 (2000-05-04), pages 1664-1669, XP002573413, ISSN: 0022-2623, DOI: 10.1021/JM9909645 [retrieved on 2000-04-18]**
- **CHAE S Y ET AL: "The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 144, no. 1, 21 May 2010 (2010-05-21), pages 10-16, XP027036550, ISSN: 0168-3659 [retrieved on 2010-04-30]**

(72) Inventors:

- **LAU, Jesper**
DK-2880 Bagsværd (DK)
- **BLOCH, Paw**
DK-2880 Bagsværd (DK)
- **KOFOED, Jacob**
DK-2880 Bagsværd (DK)
- **GARIBAY, Patrick**
DK-2880 Bagsværd (DK)

EP 2 753 642 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- GARCIA-BUSTOS J ET AL: "A BIOLOGICAL PRICE OF ANTIBIOTIC RESISTANCE: MAJOR CHANGES IN THE PEPTIDOGLYCAN STRUCTURE OF PENICILLIN-RESISTANT PNEUMOCOCCI", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 87, no. 14, 1 July 1990 (1990-07-01), pages 5415-5419, XP000138045, ISSN: 0027-8424, DOI: 10.1073/PNAS.87.14.5415